These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 6213588

  • 41. Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.
    Workman P, Ward R, Maughan TS, Newman HF, Bleehen NM.
    Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):177-81. PubMed ID: 2526107
    [Abstract] [Full Text] [Related]

  • 42. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay.
    Shibamoto Y, Streffer C, Sasai K, Oya N, Abe M.
    Int J Radiat Biol; 1992 Apr; 61(4):473-8. PubMed ID: 1349329
    [Abstract] [Full Text] [Related]

  • 43. The relationship of SR-2508 sensitizer enhancement ratio to cellular glutathione levels in human tumor cell lines.
    Mitchell JB, Phillips TL, DeGraff W, Carmichael J, Rajpal RK, Russo A.
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1143-6. PubMed ID: 2943712
    [Abstract] [Full Text] [Related]

  • 44. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
    [Abstract] [Full Text] [Related]

  • 45. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R, Workman P, Owen L.
    Int J Radiat Oncol Biol Phys; 1982 Feb; 8(3-4):473-6. PubMed ID: 7107369
    [Abstract] [Full Text] [Related]

  • 46. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.
    Hirst DG, Hazlehurst JL, Brown JM.
    Br J Cancer; 1984 Jan; 49(1):33-42. PubMed ID: 6229264
    [Abstract] [Full Text] [Related]

  • 47. [Radiosensitizing effect of a 2-nitroimidazole hydroxamate (KIN-804) to murine tumors].
    Tada T, Nakajima T, Onoyama Y, Nagasawa H, Hori H, Inayama S.
    Nihon Igaku Hoshasen Gakkai Zasshi; 1992 May 25; 52(5):688-90. PubMed ID: 1508643
    [Abstract] [Full Text] [Related]

  • 48. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH, Wallen CA, Wheeler KT.
    Int J Radiat Oncol Biol Phys; 1990 May 25; 18(5):1043-50. PubMed ID: 2140824
    [Abstract] [Full Text] [Related]

  • 49. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May 25; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 50. Pharmacokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nervous tissue.
    Sasai K, Shibamoto Y, Takahashi M, Ito T, Nishimoto S, Abe M.
    Int J Radiat Biol; 1990 May 25; 57(5):971-80. PubMed ID: 1970998
    [Abstract] [Full Text] [Related]

  • 51. Ocular absorption and toxicity of a radiosensitizer and its effect on hypoxic cells.
    Rootman J, Josephy PD, Adomat H, Palcic B.
    Arch Ophthalmol; 1982 Mar 25; 100(3):468-71. PubMed ID: 7199901
    [Abstract] [Full Text] [Related]

  • 52. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C, Mori T.
    Gan To Kagaku Ryoho; 1989 Jun 25; 16(6):2135-41. PubMed ID: 2660744
    [Abstract] [Full Text] [Related]

  • 53. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep 25; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

  • 54. Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration.
    Stratford MR, Minchinton AI, Dische S, Saunders MI, Anderson P.
    Int J Radiat Oncol Biol Phys; 1982 Sep 25; 8(3-4):377-9. PubMed ID: 7107355
    [Abstract] [Full Text] [Related]

  • 55. In vivo radiosensitizing effect of nitroimidazole derivative KIN-804.
    Tada T, Nakajima T, Onoyama Y, Murayama C, Mori T, Nagasawa H, Hori H, Inayama S.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):601-5. PubMed ID: 8005823
    [Abstract] [Full Text] [Related]

  • 56. The effects of radiosensitizers on intermediary metabolism in vivo.
    Tamulevicius P, Streffer C, Blanke G, Luscher G.
    Int J Radiat Oncol Biol Phys; 1984 Aug 15; 10(8):1387-9. PubMed ID: 6236188
    [Abstract] [Full Text] [Related]

  • 57. [Radiosensitizing effects of nitroimidazole derivative, KIN-804].
    Tada T.
    Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Jan 15; 55(1):70-5. PubMed ID: 7899069
    [Abstract] [Full Text] [Related]

  • 58. Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.
    Bonnet M, Hong CR, Wong WW, Liew LP, Shome A, Wang J, Gu Y, Stevenson RJ, Qi W, Anderson RF, Pruijn FB, Wilson WR, Jamieson SMF, Hicks KO, Hay MP.
    J Med Chem; 2018 Feb 08; 61(3):1241-1254. PubMed ID: 29253343
    [Abstract] [Full Text] [Related]

  • 59. Preparation and evaluation of suppositories for RK-28 (a new radiosensitizer) using rabbits.
    Kim NS, Umejima H, Miyata K, Okubo M, Goto S, Kato T, Mikami Y, Sagitani H, Inoue H.
    Biol Pharm Bull; 1994 May 08; 17(5):672-5. PubMed ID: 7920431
    [Abstract] [Full Text] [Related]

  • 60. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1996 May 08; 8(10-11):425-34. PubMed ID: 9114435
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.